Fig. 3.
Fig. 3. Cytotoxicity of HO-1 against Fas-positive and -negative target cells. (A) B-LCLs were established from the donor for HO-1 (Fas+/+), the patient’s father (Fas+/−), and the patient with Fas deficiency (Fas−/−). Cells were stained with FITC-conjugated mouse anti-Fas MoAb (shaded histograms) or FITC-conjugated mouse IgG (open histograms). The fluorescence profiles were analyzed with a flow cytometer. (B) HO-1–induced lysis of DEK-CAN peptide-loaded (open columns) and unloaded (shaded columns) target cells was determined by51Cr release assays over 4 hours at E:T ratios of 10:1, 5:1, and 2.5:1.

Cytotoxicity of HO-1 against Fas-positive and -negative target cells. (A) B-LCLs were established from the donor for HO-1 (Fas+/+), the patient’s father (Fas+/−), and the patient with Fas deficiency (Fas−/−). Cells were stained with FITC-conjugated mouse anti-Fas MoAb (shaded histograms) or FITC-conjugated mouse IgG (open histograms). The fluorescence profiles were analyzed with a flow cytometer. (B) HO-1–induced lysis of DEK-CAN peptide-loaded (open columns) and unloaded (shaded columns) target cells was determined by51Cr release assays over 4 hours at E:T ratios of 10:1, 5:1, and 2.5:1.

Close Modal

or Create an Account

Close Modal
Close Modal